BCL2L1 and neoplasm: We also demonstrate the efficacy of targeting BCL-XL in combination with EGFR-TKI treatment to prevent resistance, not only in cell lines but in transgenic mice, which better reflect characteristics of tumors and the tumor microenvironment, as well as anti-tumor immune responses.